1. Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high‐risk relapsed/refractory chronic lymphocytic leukemia patients. (17th September 2014) Authors: Oberic, Lucie; Vaillant, Willy; Hebraud, Benjamin; Recher, Christian; Suc, Etienne; Houyau, Philippe; Laurent, Guy; Ysebaert, Loic Journal: European journal of haematology Issue: Volume 94:Number 1(2015:Jan.) Page Start: 37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX). (September 2020) Authors: Rinaldi, Yves; Pointet, Anne-Laure; Khemissa Akouz, Faiza; Le Malicot, Karine; Wahiba, Bidaut; Louafi, Samy; Gratet, Alain; Miglianico, Laurent; Laharie, Hortense; Bouhier Leporrier, Karine; Thirot Bidault, Anne; Texereau, Patrick; Coriat, Romain; Terrebonne, Eric; Gouttebel, Marie-Claude; Malka,... Journal: European journal of cancer Issue: Volume 136(2020) Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗